Imatinib

ALL, Adult

PETHEMA FoundationSmall moleculePhase 3Active

B

62/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 89/ 100

Competitive context

73 Active assets in the ALL, Adult cohort.

Asset / Sponsor	Phase	Rating
MERCAPTOPURINE ANHYDROUS Shanxi Bethune Hospital	Phase 4	A
DEXAMETHASONE Shanxi Bethune Hospital	Phase 4	BBB
Cytosin-Arabinosid PETHEMA Foundation	Phase 4	BBB
Cyclophosphamide The First Affiliated Hospital of Zhengzhou University	Phase 4	BBB
METHOTREXATE PETHEMA Foundation	Phase 4	BBB

View all 50 →

Same molecule, other indications

Imatinib is also rated in:

chronic myeloid leukemiaDormant

BB

Indicative ·

71 / 100

blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant

BB

Indicative ·

71 / 100

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.